explore -WSS

explore

author：knowledge 2025-10-02 22:28:06 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Maui's cultural, historic landmarks damaged in the devastating wildfires

WSS

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Weight loss drugs should be covered by insurers, AMA says

Man killed during FBI raid in connection with threats against Biden, other officials

Friends ask where James Watson's attitudes about race came from

Man killed during FBI raid in connection with threats against Biden, other officials

Carbon Health diabetes program, a test of data

entertainment

explore

focus

Novavax promises a turnaround & Lilly roils the obesity market

Wegovy’s successful heart trial raises vital question about weight loss

New air purifier tech could be key to improving indoor air quality

Study suggests Covid rebound is far more common with Paxlovid than without

How one medical school became remarkably diverse

Experimental asthma app from Apple and Anthem shows promise

Dobbs anniversary: the lost opportunity of abortion as health care

Medicare’s new pay boost for primary care is angering specialists

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Publishing genetic code of viruses could cause disaster

leisure time

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Type 2 diabetes prevention programs work at large scale: study

FDA panel issues narrow recommendation for Covid vaccine booster doses

What to know about Virgin Galactic's 1st mission taking paying customers to space

Emergent cuts jobs, executive role in business shake

focus

hotspot

entertainment

explore